A citation-based method for searching scientific literature

Fengping Shao, Jun Liu, Yaoyun Duan, Li Li, Liqun Liu, Cai Zhang, Shanyang He. Biosci Rep 2020
Times Cited: 8







List of co-cited articles
31 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
62

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
50

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
658
50

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
752
50


Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
437
50

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
37

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
929
37

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
37

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
360
37

The Multifactorial Role of PARP-1 in Tumor Microenvironment.
Juan Manuel Martí, Mónica Fernández-Cortés, Santiago Serrano-Sáenz, Esteban Zamudio-Martinez, Daniel Delgado-Bellido, Angel Garcia-Diaz, Francisco Javier Oliver. Cancers (Basel) 2020
16
25

Beyond DNA repair: the novel immunological potential of PARP inhibitors.
Roman M Chabanon, Jean-Charles Soria, Christopher J Lord, Sophie Postel-Vinay. Mol Cell Oncol 2019
12
25

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
25

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Atsushi Osoegawa, Joell J Gills, Shigeru Kawabata, Phillip A Dennis. Oncotarget 2017
11
25

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
25

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
875
25

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
582
25

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
255
25

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
25

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
402
25


The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
Brian Hutton, Georgia Salanti, Deborah M Caldwell, Anna Chaimani, Christopher H Schmid, Chris Cameron, John P A Ioannidis, Sharon Straus, Kristian Thorlund, Jeroen P Jansen,[...]. Ann Intern Med 2015
25


Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Federica Tomao, Erlisa Bardhi, Anna Di Pinto, Carolina Maria Sassu, Elena Biagioli, Maria Cristina Petrella, Innocenza Palaia, Ludovico Muzii, Nicoletta Colombo, Pierluigi Benedetti Panici. Cancer Treat Rev 2019
32
25

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
344
25


Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2016
249
25

Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman. Lancet Oncol 2019
106
25

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Ann-Gerd Thorsell, Torun Ekblad, Tobias Karlberg, Mirjam Löw, Ana Filipa Pinto, Lionel Trésaugues, Martin Moche, Michael S Cohen, Herwig Schüler. J Med Chem 2017
146
25

Safety and dose modification for patients receiving niraparib.
J S Berek, U A Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, A Lesoin, N Colombo, I Vergote, O Rosengarten,[...]. Ann Oncol 2018
70
25

The kinase polypharmacology landscape of clinical PARP inhibitors.
Albert A Antolin, Malaka Ameratunga, Udai Banerji, Paul A Clarke, Paul Workman, Bissan Al-Lazikani. Sci Rep 2020
25
25

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.
Mark W Dewhirst, Yiting Cao, Benjamin Moeller. Nat Rev Cancer 2008
670
12

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Judith Michels, Ilio Vitale, Laura Senovilla, David P Enot, Pauline Garcia, Delphine Lissa, Ken A Olaussen, Catherine Brenner, Jean-Charles Soria, Maria Castedo,[...]. Cell Cycle 2013
43
12

Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.
Reem Ali, Abdulbaqi Al-Kawaz, Michael S Toss, Andrew R Green, Islam M Miligy, Katia A Mesquita, Claire Seedhouse, Sameer Mirza, Vimla Band, Emad A Rakha,[...]. Cancer Res 2018
18
12

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Rinske Drost, Kiranjit K Dhillon, Hanneke van der Gulden, Ingrid van der Heijden, Inger Brandsma, Cristina Cruz, Dafni Chondronasiou, Marta Castroviejo-Bermejo, Ute Boon, Eva Schut,[...]. J Clin Invest 2016
70
12

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán,[...]. EMBO Mol Med 2018
78
12

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
Nicola J Curtin, Yvette Drew, Sweta Sharma-Saha. Nat Rev Clin Oncol 2019
11
12

MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
Li Wang, Kathy A Mason, K Kian Ang, Thomas Buchholz, David Valdecanas, Anjili Mathur, Carolyn Buser-Doepner, Carlo Toniatti, Luka Milas. Invest New Drugs 2012
49
12

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Linda Henneman, Martine H van Miltenburg, Ewa M Michalak, Tanya M Braumuller, Janneke E Jaspers, Anne Paulien Drenth, Renske de Korte-Grimmerink, Ewa Gogola, Karoly Szuhai, Andreas Schlicker,[...]. Proc Natl Acad Sci U S A 2015
76
12

The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
Ciric To, Eun-Hee Kim, Darlene B Royce, Charlotte R Williams, Ryan M Collins, Renee Risingsong, Michael B Sporn, Karen T Liby. Cancer Prev Res (Phila) 2014
48
12

Transparent adult zebrafish as a tool for in vivo transplantation analysis.
Richard Mark White, Anna Sessa, Christopher Burke, Teresa Bowman, Jocelyn LeBlanc, Craig Ceol, Caitlin Bourque, Michael Dovey, Wolfram Goessling, Caroline Erter Burns,[...]. Cell Stem Cell 2008
711
12

VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
Concetta Saponaro, Andrea Malfettone, Girolamo Ranieri, Katia Danza, Giovanni Simone, Angelo Paradiso, Anita Mangia. PLoS One 2013
52
12

Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.
Padmini S Kedar, Donna F Stefanick, Julie K Horton, Samuel H Wilson. Mol Cancer Res 2012
39
12

The effects of radiation on angiogenesis.
Peter Grabham, Preety Sharma. Vasc Cell 2013
24
12


PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
Ahrum Min, Seock-Ah Im. Cancers (Basel) 2020
38
12

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Paul Lesueur, Justine Lequesne, Jean-Michel Grellard, Audrey Dugué, Elodie Coquan, Pierre-Emmanuel Brachet, Julien Geffrelot, William Kao, Evelyne Emery, David Hassanein Berro,[...]. BMC Cancer 2019
38
12

Zebrafish Xenografts for Drug Discovery and Personalized Medicine.
Jerry Xiao, Eric Glasgow, Seema Agarwal. Trends Cancer 2020
21
12

Brca2 (XRCC11) deficiency results in enhanced mutagenesis.
Maria Kraakman-van der Zwet, Wouter W Wiegant, Małgorzata Z Zdzienicka. Mutagenesis 2003
15
12

Interaction between PARP-1 and HIF-2α in the hypoxic response.
A Gonzalez-Flores, R Aguilar-Quesada, E Siles, S Pozo, M I Rodríguez-Lara, L López-Jiménez, M López-Rodríguez, A Peralta-Leal, D Villar, D Martín-Oliva,[...]. Oncogene 2014
31
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.